- Home
- GHY vs AVIR Comparison
GHY vs AVIR Comparison
Compare GHY & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GHY | AVIR |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.8M | 434.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GHY | AVIR |
|---|---|---|
| Price | $12.02 | $4.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 129.5K | ★ 318.4K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.25 | $2.78 |
| 52 Week High | $13.72 | $6.45 |
Technical Indicators
Market Signals| Indicator | GHY | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 34.96 |
| Support Level | $11.77 | $4.04 |
| Resistance Level | $12.10 | $4.34 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 77.78 | 18.85 |
Price Performance
Historical ComparisonAbout GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.